- Company
- Vaccine Development in 100 Days of Pandemic
- by Oct 28, 2022 05:55am
- Vaccine and bio leaders around the world have set a goal of "100 days of vaccine development" as a countermeasure to the "Next Pandemic." To achieve this, it requested organic cooperation from governments, industries, international organizations, and academia. It also predicted that Korea will play an important role in resolving the deepening in
- Company
- Influenza epidemic and the launch of generic products
- by Kim, Jin-Gu Oct 28, 2022 05:55am
- The Peramiflu-based flu treatment market, which was monopolized by GC Pharma, will be reorganized into a system in which 15 companies compete during the flu season this winter. In particular, unlike the past two years, when the number of flu patients plunged due to the prolonged COVID-19, the competition in this market is expected to be very
- Company
- The New Testament Era of Rosuzet and K-CAB
- by Chon, Seung-Hyun Oct 28, 2022 05:55am
- Domestic developed drugs continued to be strong in the foreign prescription drug market. Hanmi Pharmaceutical's complex new drug Rosuzet exceeded 100 billion won in prescriptions in three quarters, while HK inno.N's new drug K-CAB booked 100 billion won for the second consecutive year. According to UBIST, a drug research institute, on the 23r
- Policy
- The warning phrase deleting the possibility of Nucynta abuse
- by Lee, Hye-Kyung Oct 27, 2022 05:52am
- The "possibility of abuse," a warning phrase for narcotic painkillers containing Tapentadol, will be deleted. The permit includes a new disorder of resistance and opioid use, and monitoring and addiction patients consider consulting with experts. The Ministry of Food and Drug Safety announced that it will prepare a proposal for a change in pe
- InterView
- "Lilly rises in anticancer and autoimmune diseases"
- by Eo, Yun-Ho Oct 27, 2022 05:52am
- The pharmaceutical company Lilly is known for their strong diabetes treatment pipeline. As the world’s first developer of insulin, Lilly has solidified its position in the field, introducing DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 analogues into its pipeline. However, Lilly has transformed. It did not give up diabetes, the company
- Company
- Dexeryl for atopic dermatitis lands in Korea
- by Oct 27, 2022 05:52am
- Pierre Fabre Korea announced that it had launched its medical device cream ‘Dexeryl’ in Korea on the 26th. Dexeryl is an MD cream that represents the 60-year-old French pharmaceutical company, Pierre Fabre. It is used to treat dryness of the skin and symptoms from skin conditions, such as atopic dermatitis, pruritus, diabetic foot dise
- Company
- The unfinished aftershocks of COVID-19
- by Chon, Seung-Hyun Oct 26, 2022 05:50am
- The market for outpatient prescription drugs was the largest ever. This year, the prescription market has grown significantly due to the expansion of prescriptions such as cold medicine due to the rapid increase in the number of COVID-19 confirmed patients. The size of Expectant prescriptions used to relieve COVID-19 symptoms has more than doubl
- Company
- First TYK2 inhibitor Sotyktu will enter Korean market
- by Eo, Yun-Ho Oct 26, 2022 05:50am
- The oral TYK2 inhibitor for psoriasis will soon be introduced to Korea. According to industry sources, BMS Korea applied for domestic marketing authorization for its tyrosine kinase 2 (TYK2) inhibitor ‘Sotyktu (deucravacitinib) in Korea. The drug was approved for the treatment of adults with moderate-to-severe plaque psoriasis who are
- Policy
- Permission for Libtayo, a tx for skin squamous cell cancer
- by Lee, Hye-Kyung Oct 26, 2022 05:50am
- The Ministry of Food and Drug Safety (Director Oh Yu-kyung) announced on the 25th that it has approved Libtayo, a rare drug from Sanofi-Aventis Korea, for skin squamous cell cancer treatment. Libtayo is a monoclonal antibody targeting cell predetermined history 1 (PD-1)*, an immune gateway receptor for immune cells (T cells). Programmed cell
- Company
- Xarelto sales fall 30% due to generics and price cuts
- by Oct 26, 2022 05:50am
- The quarterly prescription of new oral anticoagulants (NOAC) containing rivaroxaban, which had reached KRW 15 billion, has shrunk to KRW 13 billion. This decrease is interpreted to be reflected by the price cut of Bayer’s original ‘Xarelto.’ Its generics that entered the market 1 year ago have been starting to slowly increase their share in t
